As shown in hepatocytes [35], HepG2 human hepatoma cells, and HSCs that were all treated with the saturated FA palmitate as well as mouse models of MASLD, vimentin is upregulated and secreted [29,36]. Here, VIM is linked to metabolic dysfunction-associated steatotic liver disease.